Stockscreener 앱 받기
6.68
3.33%
-0.23
전일 마감가:
$6.91
열려 있는:
$7.01
하루 거래량:
245.32K
Relative Volume:
0.86
시가총액:
$436.38M
수익:
-
순이익/손실:
$-44.47M
주가수익비율:
-6.5612
EPS:
-1.0181
순현금흐름:
$-33.50M
1주 성능:
-0.15%
1개월 성능:
+12.84%
6개월 성능:
-17.73%
1년 성능:
+18.89%
1일 변동 폭
$6.60
$7.03
1주일 범위
$6.36
$7.11
52주 변동 폭
$4.88
$9.32
Eupraxia Pharmaceuticals Inc Stock (EPRX) Company Profile
Compare EPRX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EPRX
Eupraxia Pharmaceuticals Inc
|
6.68 | 436.38M | 0 | -44.47M | -33.50M | -1.0181 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Eupraxia Pharmaceuticals Inc Stock (EPRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-23 | 개시 | William Blair | Outperform |
| 2025-07-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-06-26 | 개시 | H.C. Wainwright | Buy |
| 2025-06-16 | 개시 | Canaccord Genuity | Speculative Buy |
| 2025-02-21 | 개시 | Craig Hallum | Buy |
| 2024-11-14 | 개시 | Rodman & Renshaw | Buy |
모두보기
Eupraxia Pharmaceuticals Inc 주식(EPRX)의 최신 뉴스
Why Eupraxia Pharmaceuticals Inc stock is tanking today - Wealth Awesome
Eupraxia Pharmaceuticals Adds Veteran Drug Developers to Board as Pipeline Advances - TipRanks
Eupraxia Pharmaceuticals (EPRX) adds three drug development and commercialization experts to board - Stock Titan
Eupraxia Pharmaceuticals appoints three directors to board - Investing.com
Eupraxia Pharmaceuticals Strengthens Board with Three Industry Leaders in Drug Development and Commercialization - Investing News Network
Eupraxia Pharmaceuticals appoints three directors to board By Investing.com - Investing.com Australia
EPRX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
EPRX Technical Analysis & ETF Price Forecast - Intellectia AI
EPRX Technical Analysis & Stock Price Forecast - Intellectia AI
A3EGRS Forecast — Price Target — Prediction for 2027 - TradingView
Eupraxia Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:EPRX) - TradingView
EPRX Forecast — Price Target — Prediction for 2027 - TradingView
Oppenheimer initiates Eupraxia stock with Outperform rating By Investing.com - Investing.com Nigeria
Eupraxia Pharmaceuticals, Inc. Actuals & Estimates (FWB:X43) - TradingView
Oppenheimer Initiates Eupraxia Pharmaceuticals(EPRX.US) With Buy Rating, Announces Target Price $17 - Moomoo
X43 Forecast — Price Target — Prediction for 2027 - TradingView
Price to sales forward of Eupraxia Pharmaceuticals, Inc. – TSX:EPRX - TradingView
Price to earnings forward of Eupraxia Pharmaceuticals, Inc. – TSX:EPRX - TradingView
Enterprise value to EBITDA forward of Eupraxia Pharmaceuticals, Inc. – TSX:EPRX - TradingView
Eupraxia Pharmaceuticals (EPRX) Slips 2.19% as Stock Tests Key Support at $5.94Shakeout Pattern - dars.gov.et
Eupraxia Pharmaceuticals (EPRX) Stock Analysis Report | Financials & Insights - Benzinga
Why Eupraxia Pharmaceuticals Inc stock is rising today - Wealth Awesome
Eupraxia Pharmaceuticals Shareholders Back Board Slate and Auditor at June 18 AGM - TipRanks
Form 6K Eupraxia Pharmaceuticals Inc For: 22 June By Investing.com - Investing.com South Africa
Strong support as Eupraxia (NASDAQ: EPRX) shareholders elect seven directors, renew KPMG - Stock Titan
Eupraxia Pharmaceuticals elects all seven board nominees and reappoints KPMG as auditor at AGM. - Pluang
Eupraxia Pharmaceuticals Announces Voting Results from Annual General Meeting of Shareholders - The Manila Times
Eupraxia shareholders back all 7 directors at annual meeting - Stock Titan
Eupraxia Pharmaceuticals Announces Voting Results from Annual General Meeting of Shareholders - GlobeNewswire Inc.
Why Eupraxia Pharmaceuticals Inc stock is sliding today - Wealth Awesome
Eupraxia Pharmaceuticals Inc (EPRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Eupraxia Pharmaceuticals Inc (EPRX) Institutional Confidence - TradingKey
Eupraxia Pharmaceuticals Inc (EPRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Eupraxia Pharmaceuticals Inc (EPRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Eupraxia Pharmaceuticals Inc (EPRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Eupraxia Pharmaceuticals Inc - TradingKey
Eupraxia Pharmaceuticals Inc (EPRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Eupraxia Pharmaceuticals Inc (EPRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Why Eupraxia Pharmaceuticals Inc stock is skyrocketing today - Wealth Awesome
Why Eupraxia Pharmaceuticals Inc stock is plummeting today - Wealth Awesome
Eupraxia Pharmaceuticals Inc (EPRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
This SailPoint analyst begins coverage on a bullish note; here are top 3 initiations for Thursday - MSN
Eupraxia Pharmaceuticals Q1 2026 Earnings: Narrow Loss Misses Estimates as Clinical Pipeline AdvancesNext Quarter Guidance - dars.gov.et
Eupraxia Pharmaceuticals, Inc. Financial Disclosures & Filings - TradingView
EPRX Q1 2026 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Reports No Revenue - dars.gov.et
EPRX Q1 2026 Earnings: Wider-Than-Expected Loss Weighs on SharesDebt Analysis Report - newsline.com
Osteoarthritis Market Gains Momentum with Expanding Pipeline and Investment Potential by 2036 – DelveInsight | Merck KGaA, Peptinov, LG Chem, Akan Bioscience, BioTissue,Inc., Eupraxia Pharma - Barchart
Eupraxia Pharmaceuticals Confirms Mailing of 2026 Proxy Materials to Shareholders - The Globe and Mail
Eupraxia Pharmaceuticals Sets June 18, 2026 Virtual AGM and Files May Form 6-K - TipRanks
Eupraxia (EPRX) details 2026 virtual AGM, board nominees and pay plan - Stock Titan
Eupraxia Pharmaceuticals (EPRX) confirms mailing of proxy materials to holders - Stock Titan
Eupraxia Pharmaceuticals Inc (EPRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.64%
자본화:
|
볼륨(24시간):